Updates from the CRS team — new studies, milestones, events, and practical perspectives on generating clinical evidence for medtech in the UK.
Part IX is being reformed. Under the new Enhanced Assessment Framework, every wound and skin care product — new listing or renewal — will be scored out of 100 on quality, social value and price. The quality evidence has the longest lead time, and it has to be gathered, analysed and written up before you can apply. We build that evidence base before the window opens, mapped directly to NHSBSA's scoring criteria.
Talk to us about Part IX readiness →Our CEO and PCRA Research Chair on how UK medtech can generate credible, affordable real-world evidence inside the NHS.
Read more →How we designed a sub-bandage compression study to a standard robust enough for peer-reviewed publication.
Read more →A clinician-led evidence programme that took an innovative wound care therapy from promising results to wider NHS availability.
Read more →Being embedded in primary and secondary care — not renting access — is what removes the site set-up lag.
Read more →A plain-English guide to running your whole trial with us, or bringing us in only for the parts you need.
Read more →Full-service delivery inside a tightly regulated NHS environment, with no reported quality or data integrity concerns.
Read more →We’re hearing from experienced, independent clinical research professionals across the UK.
Read more →Tell us what you're working on and we'll keep you posted on relevant studies, events and evidence insights.